Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAF V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST).
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Mark W. Kieran, Darren R Hargrave, Kenneth J. Cohen, Isabelle Aerts, Ira J. Dunkel, Trent Ryan Hummel, Irene Jimenez, Andrew DJ Pearson, Christine A. Pratilas, James Whitlock, Eric Bouffet, Wei-Ping Violet Shen, Alberto Broniscer, Anne-Isabelle Bertozzi, Joan L Sandberg, Allison M. Florance, Benjamin B. Suttle, Pat Haney, Mark W. Russo, Birgit Geoerger
Institutions: Dana-Farber Cancer Institute, Great Ormond Street Hospital, Great Ormond Street Hospital for Children NHS Foundation Trust, Johns Hopkins University, Institut Curie, Memorial Sloan Kettering Cancer Center, Cincinnati Children's Hospital Medical Center, Royal Marsden Hospital, Hospital for Sick Children, Children's Hospital of Orange County, St. Jude Children's Research Hospital, Centre Hospitalier Universitaire de Toulouse, GlaxoSmithKline (United States), Institut Gustave Roussy
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2602986569